Abstract:Objective: To explore the effects of FK506 on the inhibition of cell proliferation and the expression of cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS) and their products PGE(2) and NO in TNF-alpha-stimulated human rheumatoid arthritis synovial fibroblasts (RASF) treated with triptolide (TP), and to study the mechanisms involved when combining FK506 and TP in RA therapy.Materials and Methods: RASF used in the experiments were obtained from the synovial tissue of patients with RA before being cultured. RASF were pretreated with FK506 (10 similar to 1000 nM) for 2 hours before being stimulated with TNF-alpha (20 ng/ml) in the presence or absence of TP (10 ng/ml). RASF proliferation was determined by [H-3]-TdR incorporation. Production of PGE(2) and NO in culture supernatants of RASF was detected by competitive ELISA and enzymatic reduction of nitrate, respectively. Expressions of COX-2 and iNOS mRNA in RASF were analyzed by semi-quantitative RT-PCR. Expressions of COX-2 and iNOS protein were estimated by Western-blot and a cellular enzyme immunoassay. NF kappa B activity in wholecell extract of treated RASF was also measured using an ELISA-based method.Results: Neither FK506 nor TP at a lower concentration (10 ng/ml) affected TNF-alpha-induced COX-2 and iNOS expressions or PGE(2), and NO productions in synovial cells. Combined treatment of FK506 and a lower concentration of TP (10 ng/ml) reduced both COX-2 and iNOS mRNA and protein expression, and correspondingly reduced PGE(2) and NO produced by synovial fibroblasts. This effect was highly correlated with FK506 concentration (10 similar to 1000 nM. NF kappa B activity in TNF-alpha-stimulated synovial cells was suppressed more profoundly by FK506 plus TP (10 ng/ml) than by TP (10 ng/ml) alone. However, no change was observed regarding the inhibition of synovial cell proliferation after combined treatment of FK506 and TP.Conclusion: FK506 enhanced TP-mediated down-regulation of COX-2 and iNOS as well as their products PGE(2), and NO in human TNF-alpha-stimulated RASF by more profoundly suppressing the activity of NF kappa B.

Effect of Teriflunomide Combined with Methotrexate on Fibroblast-like Synoviocytes in Rheumatoid Arthritis

The efficacy and safety of iguratimod or leflunomide combined with methotrexate in treating active rheumatoid arthritis (TRANMOD): a multicenter, randomized, double-blinded, double dummy and controlled clinical trial

Osteoclast Differentiation Inhibited by Active Metabolite of Leflunomide through Regulating NFATc1 Expression

[Effects of Leflunomide and Its Active Metabolite on the Production and Mrna Expression of TNF-alpha in Peritoneal Macrophages and Synovial Cells with Adjuvant Arthritis in Rats].

[Effects of Sinomenine and Methotrexate on Fibroblast-Like Synoviocytes in Rheumatoid Arthritis].

Enhancement by FK506 of Triptolide-induced Inhibition of Expression of COX-2 and Inos in Human Rheumatoid Arthritis Synovial Fibroblasts

Combination of MTX and LEF Attenuates Inflammatory Bone Erosion by Down-Regulation of Receptor Activator of NF-kB Ligand and Interleukin-17 in Type II Collagen-Induced Arthritis Rats

Evaluation of the clinical and radiological.efficacy of recombinant human TNFR Ⅱ -Fc combined with methotrexate in the treatment of moderate and severe rheumatoid arthritis

Methotrexate promotes the release of granulocyte–macrophage colony-stimulating factor from rheumatoid arthritis fibroblast-like synoviocytes via autocrine interleukin-1 signaling

A Double-Blind, Double-Dummy, Randomized Controlled, Multicenter Trial Of Tc-99-Methylene Diphosphonate In Patients With Moderate To Severe Rheumatoid Arthritis

Leflunomide, a New Disease-Modifying Drug for Treating Active Rheumatoid Arthritis in Methotrexate-Controlled Phase II Clinical Trial.

Efficacy and safety of tofacitinib combined with methotrexate in the treatment of rheumatoid arthritis: A systematic review and meta-analysis.

Effectiveness and Safety of Methotrexate Versus Leflunomide in 12-Month Treatment for Takayasu Arteritis.

A comparison study of a recombinant tumor necrosis factor receptor:Fc fusion protein (rhTNFR:Fc) and methotrexate in treatment of patients with active rheumatoid arthritis in China

Clinical Analysis of Chinese Patients With Rheumatoid Arthritis Treated With Leflunomide and Methotrexate Combined With Different Dosages of Glucocorticoid

Study on the Mechanism of the Combination of Methotrexate and Leflunomide in the Treatment of Rheumatoid Arthritis Based on Network Pharmacology, Molecular Docking, and in vitro Experimental Verification

FK506 Enhances Triptolide-Induced Down-Regulation of Cyclooxygenase-2, Inducible Nitric Oxide Synthase As Well As Their Products PGE2 and NO in TNF-alpha-stimulated Synovial Fibroblasts from Rheumatoid Arthritic Patients.

Efficacy of Leflunomide Plus Methotrexate for Psoriatic Arthritis

[Therapeutic Effect and Impact on Cytokine Production by Methotrexate in Rheumatoid Arthritis].

Efficacy of methotrexate and etanercept biosimilar rhTNFR:Fc in Chinese patients with active rheumatoid arthritis: A controlled, randomized and multicenter study

ReABLE study on the efficacy and long-term safety of recombinant human tumor necrosis factor-α receptor Ⅱ IgG Fc fusion protein with methotrexate in active rheumatoid arthritis